We demonstrated the clinical utility of molecular phenotyping in clinical hemoglobinopathies by mapping out the spectrum of heterozygous HbE, HbD and a heterozygous beta thalassemia (HBB:c.27_28insG) variants (Fig. 5 and Table 2). Here, HBD is linked to beta thalassemia.